Send to

Choose Destination
BMJ Open. 2018 Jun 8;8(6):e020638. doi: 10.1136/bmjopen-2017-020638.

Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer's disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol.

Author information

Personal Social Services Research Unit, Department of Health Policy, London School of Economics and Political Science, London, UK.
Nuffield Department of Population Health, Health Economics Research Centre, Oxford, UK.
Department of Health Policy, London School of Economics and Political Science, London, UK.
GPORWE International, Eli Lilly Limited, Erl Wood Manor, Windlesham, UK.
F. Hoffmann-La Roche Ltd, MORSE Health Technology Assessment Group, Basel, Switzerland.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands.
Department of Neurobiology, Care Science and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden.
Global Head Health Economic Modelling and Methodology, Basel, Switzerland.



Dementia is one of the greatest health challenges the world will face in the coming decades, as it is one of the principal causes of disability and dependency among older people. Economic modelling is used widely across many health conditions to inform decisions on health and social care policy and practice. The aim of this literature review is to systematically identify, review and critically evaluate existing health economics models in dementia. We included the full spectrum of dementia, including Alzheimer's disease (AD), from preclinical stages through to severe dementia and end of life. This review forms part of the Real world Outcomes across the Alzheimer's Disease spectrum for better care: multimodal data Access Platform (ROADMAP) project.


Electronic searches were conducted in Medical Literature Analysis and Retrieval System Online, Excerpta Medica dataBASE, Economic Literature Database, NHS Economic Evaluation Database, Cochrane Central Register of Controlled Trials, Cost-Effectiveness Analysis Registry, Research Papers in Economics, Database of Abstracts of Reviews of Effectiveness, Science Citation Index, Turning Research Into Practice and Open Grey for studies published between January 2000 and the end of June 2017. Two reviewers will independently assess each study against predefined eligibility criteria. A third reviewer will resolve any disagreement. Data will be extracted using a predefined data extraction form following best practice. Study quality will be assessed using the Phillips checklist for decision analytic modelling. A narrative synthesis will be used.


The results will be made available in a scientific peer-reviewed journal paper, will be presented at relevant conferences and will also be made available through the ROADMAP project.




Alzheimer’s disease; dementia; disease progression; economic model; systematic review

Conflict of interest statement

Competing interests: AT-H is an employee of Eli Lilly and Company Limited and owns stock in Eli Lilly and Company Limited. AYCS is an employee of F. Hoffmann-La Roche Ltd. RH reports grants from ROADMAP (IMI2; public-private collaboration; 2016–2019) to conduct this study, grants from BIOMARKAPD (EU JPND project; 2012–2016), grants from Actifcare (EU JPND project; 2014–2017), grants from European Brain Council (VoT project; public–private collaboration; 2017), grants from Dutch Flutemetamol Study (public–private collaboration; 2012–2017), personal fees from Piramal (advisory; 2016), personal fees from Roche (advisory; 2017), outside the submitted work. PL is employed by, owns stock in and has stock options in Novartis Pharma AG. Novartis Pharma AG, GE Healthcare, Biogen, Eli Lilly and Company Limited and Roche are industry partners in the ROADMAP Project.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center